Granules India Limited announced robust financial results for the second quarter and half-year of FY27. Revenue surged by 20% year-on-year to INR15,600 million, marking a significant milestone. EBITDA grew by 21%, and PAT saw a substantial increase of 39% to INR1,818 million. The company highlighted strong performance across its business segments, including controlled substances and its peptide CDMO business, and provided an update on its Gagillapur facility’s FDA inspection.
Granules India Reports Robust Q2 FY27 Performance
Granules India Limited has announced its financial results for the second quarter and half-year ended November 02, 2026. The company reported a significant 20% year-on-year revenue growth, reaching INR15,600 million for the quarter, surpassing the INR15,000 million mark for the first time. This marks the eighth consecutive quarter of sequential revenue growth.
Key Financial Highlights
- Revenue Growth: Increased by 20% year-on-year to INR15,600 million in Q2 FY27.
- EBITDA: Grew by 21% year-on-year.
- Profit After Tax (PAT): Increased by 39% to INR1,818 million.
- Gross Margins: Stood at 64.4%, despite higher input costs.
- EBITDA Margin: Was 21.6%.
Operational Updates and Strategy
The company provided an update on its Gagillapur facility, where a U.S. FDA conducted a cGMP inspection from October 19 to October 30. The inspection concluded with a Form 483 containing eleven observations, none of which relate to data integrity, cross-contamination, or facility upkeep. Granules India is confident that these observations are addressable and will submit a comprehensive response within 15 business days. The company reiterated its focus on controlled substances, complex generics, geographical expansion, oncology, and peptide CDMO as key growth pillars. Significant progress is being made in its R&D and product development strategy, with filings for several sole first-to-file ANDAs expected.
Peptide CDMO and US Operations
Senn Tides, the peptide CDMO business, is showing strong momentum with successful GMP inspections in Zurich and renewed engagements with major CDMO players. The company is advancing its CRDMO platform and has strengthened its oligonucleotide scientific leadership. In the U.S., Granules India holds the #3 market share in controlled substances.
Financial Outlook
The company maintains a positive outlook, emphasizing disciplined execution, strengthening quality, and delivering reliability to customers. While facing input cost pressures due to geopolitical developments, Granules India is actively working with customers to pass on increases. The company is confident in its growth trajectory, driven by a diversified portfolio, enhanced development capabilities, and strategic investments in capacity expansion and R&D.
Source: BSE
